Lexeo Therapeutics(LXEO) - 2024 Q1 - Quarterly Results
Exhibit 99.1 Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights Closed an oversubscribed 195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions Interim read ...